HPV Vaccine's Long-Term power tested in rwandan women
NCT ID NCT05247853
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at how well the HPV vaccine protects against HPV infections over time in over 3,000 Rwandan women aged 18-28, some living with HIV and some without. Researchers collected blood, oral, and other samples to measure vaccine effectiveness and long-term antibody levels. They also tested a low-cost, point-of-care antibody test to see if it can confirm HPV vaccination status.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could confirm that the HPV vaccine provides long-lasting protection for women with HIV, and validate a cheap test to check vaccination status.
- What could go wrong
- This is an observational study, not a treatment trial. Results may not apply to other populations, and the low-cost test might not be accurate enough.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rwanda Military Hospital
Kigali, Rwanda
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can an antiviral make radiation more effective against cervical cancer?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Can a Two-Antibody combo outsmart advanced cancer?
- Can robotic surgery match open surgery in beating cervical cancer?
- Blood test clues could sharpen cervical cancer treatment